What was the most frequently reported adverse reaction in placebo-controlled trials of fampridine in patients with multiple sclerosis?

Urinary tract infection was the most frequently reported adverse reaction in placebo-controlled trials of fampridine at the recommended dose in patients with multiple sclerosis, occurring in approximately 12% of patients.